Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nobelpharma Launches China Subsidiary
January 13, 2021
- Health Damages Linked to Kobayashi Kako Issue Rise to 210
January 13, 2021
- SymBio’s Anticancer Agent Treakisym Now Available in RTD Formulation
January 13, 2021
- Kobayashi Kako Expected to Face Administrative Penalty This Fiscal Year, Biz Suspension Likely
January 12, 2021
- Drug Makers, Wholesalers Boost WFH as Japan Declares Second Emergency
January 12, 2021
- Takeda Rolls Out Early Training Program for Young Management Candidates
January 12, 2021
- Meiji’s Belumosudil Enters Japan PI Study for cGVHD
January 12, 2021
- Japan Ethical Drug Sales Down 6.1% in November: Crecon
January 12, 2021
- Keytruda Tops in 2020 Drug Ranking for 2 Years in Row; Sales of 3 Cancer Meds Exceed 100 Billion Yen
January 8, 2021
- Keytruda Best-Selling Drug in December: Encise
January 8, 2021
- ASKA Grants Exclusive Chinese Sales Rights for Altat to Local Firm
January 8, 2021
- LEO Pharma Earns Approval for Dovobet Foam Version
January 7, 2021
- Relugolix Now Available for Advanced Prostate Cancer in US
January 7, 2021
- Mirabegron Gets FDA’s Priority Review for Pediatric NDO: Astellas
January 7, 2021
- Kyowa Kirin Begins Japan PIII for Bardoxolone in ADPKD
January 7, 2021
- Fujifilm to Set Up Viral-Vector Contract Manufacturing Hub in Boston Area
January 6, 2021
- Sosei Regains Global Rights to Muscarinic Agonist Programs from AbbVie, CEO Says It’s Not Bad News
January 6, 2021
- Meiji Pharma Fortifies US Foothold with New Subsidiary
January 6, 2021
- JCR Inks Domestic Production Deal for AstraZeneca COVID-19 Vaccine Solution
January 6, 2021
- Takeda Closes Sales of 16 Non-Core Meds to Germany’s Cheplapharm
January 6, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…